AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales
October 19 2020 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced the appointment of
David Crist as Vice President of Sales. In this role, Mr. Crist
will be responsible for building out AVEO’s sales force in
anticipation of the potential approval and launch of tivozanib, the
Company’s next-generation vascular endothelial growth factor
receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for
relapsed or refractory renal cell carcinoma.
“We are excited to welcome David to the AVEO team as we continue
to prepare for the potential commercial launch of tivozanib in the
U.S.,” said Mike Ferraresso, senior vice president, business
analytics and commercial operations of AVEO. “David’s proven track
record of success and deep experience with the launch and growth of
new oncology therapies will play an important role in the success
of our commercial strategy and team. Our commercial team and I look
forward to working closely with him throughout this process.”
“I am pleased to join AVEO during this transformational period
for the Company, as it prepares for the potential launch of
tivozanib in the U.S.,” said Mr. Crist. “I believe that tivozanib
has the potential to be an important new treatment option for
patients with relapsed or refractory renal cell carcinoma with what
would be the first evidence-based roadmap for treatment decisions
in the third-plus-line setting, including for patients receiving
earlier-line immunotherapy. I look forward to working alongside
this talented team as AVEO moves toward the potential
commercialization of tivozanib in the U.S.”
Mr. Crist brings more than twenty years of oncology sales
experience in both launch-stage and late-stage companies, building
commercial organizations and developing high performing sales force
teams. During his career, Mr. Crist held oncology-focused sales
roles at several leading pharmaceutical companies including MGI
(Molecular Genetics, Inc), Eisai, Sanofi Genzyme, GlaxoSmithKline
and ARIAD Pharmaceuticals, where he led their sales organization in
the successful relaunch of ICLUSIG® (ponatinib), which contributed
to the acquisition of ARIAD by Takeda Oncology in 2017. Following
the acquisition, he continued at Takeda to successfully launch
ALUNBRIG® (brigatinib), which exceeded launch year and subsequent
year forecasts nationally. Directly prior to joining AVEO, Mr.
Crist served as general manager, hematology oncology U.S. franchise
at argenx, a global immunology company, where he led commercial
development for two of the company’s hematology and oncology
compounds. Mr. Crist holds a B.S. from Florida State
University.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology focused biopharmaceutical company committed
to delivering medicines that provide a better life for cancer
patients. AVEO’s strategy is to focus its resources toward
development and commercialization of its product candidates in
North America, while leveraging partnerships to support development
and commercialization in other geographies. AVEO’s lead candidate,
tivozanib is approved as FOTIVDA® in the European Union and other
countries in the EUSA territory for the treatment of adult patients
with advanced renal cell carcinoma. AVEO is working to develop and
potentially commercialize tivozanib in the U.S. as a treatment for
renal cell carcinoma and hepatocellular carcinoma. AVEO has
previously reported promising early clinical data on ficlatuzumab
(anti-HGF mAb) in head and neck cancer, acute myeloid leukemia and
pancreatic cancer and is conducting a randomized Phase 2
confirmatory clinical trial of ficlatuzumab in head and neck
cancer. AVEO’s earlier-stage pipeline includes several monoclonal
antibodies in oncology development, including AV-203 (anti-ErbB3
mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb). AVEO
is committed to creating an environment of diversity and inclusion
as a foundation for innovation.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. The words
“anticipate,” “believe,” “expect,” “hope,” “intend,” “may,” “plan,”
“potential,” “could,” “should,” “would,” “seek,” “look forward,”
“advance,” “goal,” “strategy,” or the negative of these terms or
other similar expressions, are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include,
among others, statements about: the potential for tivozanib as a
treatment option for patients with advanced HCC or
relapsed/refractory or advanced RCC; the potential efficacy,
safety, and tolerability of tivozanib, both as a stand-alone drug
candidate and in combination with immunotherapy; AVEO’s execution
of its clinical and regulatory strategy for tivozanib; AVEO’s plans
and strategies for current and future clinical trials of tivozanib,
ficlatuzumab and AV-380 and for commercialization of tivozanib in
the United States; and AVEO’s strategy, prospects, plans and
objectives for its product candidates and for the Company
generally. AVEO has based its expectations and estimates on
assumptions that may prove to be incorrect. As a result, readers
are cautioned not to place undue reliance on these expectations and
estimates. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements that AVEO makes due to a number of
important factors, including risks relating to: whether the results
of TIVO-3 are sufficient to obtain marketing approval for tivozanib
in the U.S., which turns on the ability of AVEO to demonstrate to
the satisfaction of the FDA the safety and efficacy of tivozanib
based upon the findings of TIVO-3, including its data with respect
to PFS, the rate of adverse events, OS and other information that
the FDA may consider to be relevant to an approval determination;
AVEO’s ability, and the ability of its licensees, to demonstrate to
the satisfaction of applicable regulatory agencies such as the FDA
the safety, efficacy and clinically meaningful benefit of AVEO’s
product candidates, including, in particular, tivozanib and
ficlatuzumab; and AVEO’s ability to enter into and maintain its
third party collaboration and license agreements, and its ability,
and the ability of its strategic partners, to achieve development
and commercialization objectives under these arrangements. AVEO
faces other risks relating to its business as well, including risks
relating to the timing and costs of seeking and obtaining
regulatory approval; AVEO’s and its collaborators’ ability to
successfully enroll and complete clinical trials; AVEO’s ability to
maintain compliance with regulatory requirements applicable to its
product candidates; AVEO’s ability to obtain and maintain adequate
protection for intellectual property rights relating to its product
candidates; AVEO’s ability to successfully implement its strategic
plans, including its ability to successfully launch and
commercialize tivozanib if it may be approved for commercialization
by the FDA; AVEO’s ability to raise the substantial additional
funds required to achieve its goals, including those goals
pertaining to the development and commercialization of tivozanib;
unplanned capital requirements; AVEO’s ability to access future
borrowings under the Hercules loan facility, which turns on the
achievement of milestones related to the approval and
commercialization of tivozanib in the U.S., which milestones may
not be achieved; adverse general economic and industry conditions;
the potential adverse effects of the COVID-19 pandemic on AVEO’s
business continuity, financial condition, results of operations,
liquidity and ability to successfully and timely enroll, complete
and read-out data from its clinical trials; competitive factors;
and those risks discussed in the sections titled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations—Liquidity and Capital Resources” included in
AVEO’s quarterly and annual reports on file with the Securities and
Exchange Commission (SEC) and in other filings that AVEO makes with
the SEC. The forward-looking statements in this press release
represent AVEO’s views as of the date of this press release, and
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO's views as of any date other than
the date of this press release.
Any reference to AVEO’s website address in this press release is
intended to be an inactive textual reference only and not an active
hyperlink.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005137/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024